All News

Artificial retina engineered from ancient protein now in space

The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.

Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

ARVO sets stage for virtual event

‘Revolutionary Eye and Vision Research’ theme of annual meeting.